```html

Quenched Psychosis (Drug‑Induced)

Overview

Quenched psychosis is a term sometimes used in clinical literature to describe a brief, drug‑induced psychotic episode that resolves quickly once the offending substance is discontinued or cleared from the body. It is most often seen after acute exposure to high‑potency hallucinogens (e.g., LSD, psilocybin), synthetic cannabinoids, stimulant drugs (e.g., methamphetamine, cocaine), or certain prescription medications (e.g., high‑dose corticosteroids, anticholinergics).

People of any age can be affected, but the highest incidence occurs in:

• Young adults (18‑30 years) who use recreational drugs.
• Individuals with a personal or family history of mood or psychotic disorders.
• Patients receiving high‑dose or rapidly titrated psychiatric or endocrine medications.

While exact prevalence is difficult to quantify—because cases are often under‑reported—the National Institute on Drug Abuse (NIDA) estimates that **≈1 % of annual recreational drug users experience a drug‑induced psychotic episode**, and a subset of these present as “quenched” (self‑limited) psychosis within hours to a few days after exposure.<sup>1</sup>

Symptoms

Symptoms usually appear within minutes to hours after drug ingestion and tend to resolve within 24–72 hours once the drug is metabolized. The presentation can mimic primary psychotic disorders, but the abrupt onset and rapid resolution are key clues.

• Hallucinations – visual (e.g., patterns, geometric shapes), auditory (voices), tactile (feeling bugs crawling), or olfactory.
• Delusions – fixed false beliefs such as persecution, grandeur, or bizarre ideas about the drug’s effects.
• Disorganized thinking – loose associations, incoherent speech, or rapid, nonsensical thought flow.
• Paranoia – intense suspicion that others are plotting harm.
• Agitation or extreme restlessness – pacing, inability to sit still, or sudden bursts of activity.
• Emotional lability – rapid shifts from euphoria to anxiety, fear, or dysphoria.
• Impaired insight – the person may not recognize that their experiences are drug‑related.
• Short‑term memory deficits – difficulty recalling recent events.
• Physical signs – tachycardia, hypertension, diaphoresis, dilated pupils, or tremor (often drug‑specific).

Because the symptoms are short‑lived, patients and clinicians may miss the episode if they are not present during the acute phase.

Causes and Risk Factors

Primary Causes

1. Hallucinogens – LSD, psilocybin, DMT, PCP, and synthetic cannabinoids can trigger intense perceptual distortions that evolve into psychosis.
2. Stimulants – High doses of cocaine, methamphetamine, or amphetamine‑type prescription drugs (e.g., Adderall) increase dopamine transmission, precipitating psychotic symptoms.
3. Anticholinergic toxicity – Overdose of drugs such as atropine, antihistamines, or certain antidepressants can cause delirium with psychotic features.
4. Corticosteroids – High‑dose prednisone or dexamethasone can produce mood swings, mania, and psychosis, especially when used > 40 mg/day for > 2 weeks.<sup>2</sup>
5. Other medications – Certain anti‑epileptics (e.g., levetiracetam), immunosuppressants (e.g., tacrolimus), and anti‑Parkinson agents (e.g., levodopa) have been implicated.

Risk Factors

• Previous psychiatric illness (schizophrenia, bipolar disorder, major depression).
• Family history of psychosis or mood disorders.
• Polysubstance use or simultaneous ingestion of multiple psychoactive agents.
• High‑dose or rapid escalation of drug dosage.
• Underlying medical conditions that affect drug metabolism (e.g., liver disease, renal impairment).
• Adolescence or early adulthood – the brain is still maturing, making it more vulnerable to dopaminergic surges.

Diagnosis

Diagnosing quenched psychosis relies on a careful history, clinical observation, and exclusion of other causes.

Step‑by‑step approach

1. Clinical interview – Determine the exact timing of symptom onset relative to drug exposure, dose, route, and co‑ingestants.
2. Physical examination – Look for signs of intoxication, vital‑sign abnormalities, or withdrawal.
3. Laboratory tests – Basic metabolic panel, liver function tests, and toxicology screen (urine or serum) to confirm presence of the suspected drug.
4. Psychiatric assessment tools – Brief Symptom Rating Scale (BSRS) or Positive and Negative Syndrome Scale (PANSS) can quantify psychotic severity.
5. Neuroimaging (if indicated) – MRI or CT only when structural brain disease, head trauma, or cerebrovascular accident is suspected.
6. Rule‑out medical mimics – Infections (e.g., meningitis), metabolic disturbances (e.g., hypoglycemia, electrolyte imbalance), or endocrine disorders (e.g., thyroid storm).

According to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM‑5), the episode is classified under “Substance‑Induced Psychotic Disorder” when:

• Psychotic symptoms develop during or shortly after intoxication, withdrawal, or exposure to a drug.
• The symptoms are not better explained by a primary psychotic disorder.
• They resolve within a month after cessation of the substance (often sooner for “quenched” cases).

Treatment Options

Management focuses on rapid symptom control, safety, and prevention of recurrence.

Acute Pharmacologic Management

• Antipsychotics – Low‑dose oral haloperidol (1–5 mg) or atypical agents (e.g., risperidone 0.5–2 mg) are first‑line for severe hallucinations or agitation. Intramuscular formulations are useful if the patient is combative.
• Benzodiazepines – Lorazepam 0.5–2 mg IV/IM for agitation, anxiety, or seizures associated with stimulant overdose.
• Supportive care – Intravenous fluids, oxygen, and correction of electrolyte abnormalities.

Non‑pharmacologic Interventions

• Safe, low‑stimulus environment (dim lighting, minimal noise).
• Reorientation techniques – repeated gentle reminders of time, place, and identity.
• Monitoring for self‑harm or aggression.

Long‑Term Management

• Medication taper – For corticosteroid‑induced cases, gradually reduce the dose under physician supervision.
• Psychiatric follow‑up – Evaluate for persistent symptoms or emergence of a primary psychotic disorder (≈10‑15 % of drug‑induced cases develop lasting illness).<sup>3</sup>
• Substance‑use counseling – Cognitive‑behavioral therapy (CBT) or Motivational Interviewing can reduce future risky use.
• Peer support groups – Narcotics Anonymous, SMART Recovery, or similar programs.

Living with Quenched Psychosis (Drug‑Induced)

Even though the acute episode is brief, patients often experience anxiety, guilt, or fear of recurrence. Practical strategies to promote recovery include:

• Maintain a drug‑free diary – Record any substance use, dose, and associated feelings to identify triggers.
• Establish a structured routine – Regular sleep, meals, and exercise help stabilize neurotransmitter balance.
• Stress‑reduction practices – Mindfulness meditation, yoga, or deep‑breathing exercises reduce anxiety that can precipitate relapse.
• Stay connected – Keep open communication with trusted friends or family members who can intervene if substance use re‑begins.
• Medication adherence – If an antipsychotic is prescribed for a lingering mood or psychotic symptom, take it exactly as directed.
• Regular medical review – Annual check‑ups with a primary care provider and mental‑health professional.

Prevention

Preventing drug‑induced psychosis is primarily about reducing exposure and enhancing resilience.

• Education – Knowledge of the psychosis‑risk profile of specific substances (e.g., high‑potency synthetic cannabinoids).
• Prescription vigilance – Doctors should prescribe the lowest effective dose of corticosteroids or stimulants and provide clear tapering plans.
• Screening – Routine mental‑health screening before initiating high‑risk medications.
• Harm‑reduction tools – If drug use continues, provide resources such as drug‑checking services, supervised consumption sites, and naloxone kits (for opioid overlap).
• Family involvement – Encourage loved ones to recognize early warning signs and seek help promptly.

Complications

While most cases resolve quickly, untreated or recurrent episodes can lead to serious outcomes:

• Persistent psychotic disorder (up to 15 % conversion rate).
• Self‑harm or suicide attempts during intense paranoia or hallucinations.
• Accidents or injuries due to impaired perception (e.g., falls, motor‑vehicle crashes).
• Substance dependence or escalation to more potent drugs.
• Social and occupational dysfunction – loss of job, strained relationships, or legal issues.

When to Seek Emergency Care

References

1. National Institute on Drug Abuse. Hallucinogen Use and Risk of Psychosis. 2022. https://www.drugabuse.gov
2. Mayo Clinic. Corticosteroid side effects: psychosis and mood changes. 2023. https://www.mayoclinic.org
3. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. 2021.
4. World Health Organization. Guidelines for the Management of Substance Use Disorders. 2022.
5. Cleveland Clinic. Drug‑Induced Psychosis: Recognition and Management. 2023.

```